DexCom, Inc. provided earnings guidance for the year 2024. For the year, the company expects revenue of approximately $4.20 billion to $4.35 billion (17% - 21% organic growth).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.4 USD | -0.42% | +3.39% | +5.86% |
Apr. 30 | Glutality Powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology | CI |
Apr. 26 | Wall Street: the worst week of 2024 is followed by the best | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.86% | 52.24B | |
-5.43% | 181B | |
+4.30% | 114B | |
-3.09% | 68.29B | |
+8.15% | 44.3B | |
+7.52% | 42.73B | |
+25.54% | 32.52B | |
+17.85% | 26.02B | |
+1.00% | 25.91B | |
-1.25% | 24.72B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- DexCom, Inc. Provides Earnings Guidance for the Year 2024